BioSpace News Archive

- Roivant plans to initiate Phase 2 clinical trial in 2019

-Grant award to advance RAL GTPase inhibitors in KRAS mutant solid tumors models with Machavert’s drug delivery platform-

ALCF’s 13th Annual gala brings together lung cancer patients and their families to recognize dedicated researchers and clinicians

reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)

Tiziana Life Sciences plc today announces the pricing of its underwritten initial public offering in the United States (the “Offering”) of 442,910 American Depositary Shares (“ADSs”), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company (“Ordinary Shares”) at an initial public offering price of $9.90 per ADS, before underwriting discounts and commissions.

Milkshake promotion in honor of Children’s Day

The PEPFAR Extension Act of 2018 (the President’s Emergency Fund for AIDS Relief) was approved by unanimous voice vote in US House of Representatives late last week and sent on to the U.S. Senate.

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, is investigating Birner Dental Management, Inc. (''BDMS’’ or the ''Company’’) (OTC: BDMS) relating to the sale of the Company to Mid-Atlantic Dental Services Holdings, LLC.

Alma, one of the top five global leaders of energy-based medical and aesthetic solutions, today announced it has completed the first step of acquiring its Israeli distributor Nova Medical, extending its business outreach and establishing a direct operation in Israel.

Plug & Play Platform Continues to be Recognized for Distinct Benefits